TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04969731: An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After

Sponsor: GC Cell Corporation · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT04969731 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04969731 Rescue Dossier →